Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.40 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138032 | 0.94 | C5AR1 (0.43) | C5AR1TRPM8DHFRTSHRMMP13 | |
| SCHEMBL5136840 | 0.92 | C5AR1 (0.41) | C5AR1TRPM8DHFRTSHRMMP13 | |
| SCHEMBL5136018 | 0.91 | C5AR1 (0.41) | C5AR1TRPM8DHFRTSHRMMP13 | |
| SCHEMBL5136208 | 0.91 | CRHR1 (0.43) | C5AR1TRPM8DHFRTSHRPPARG | |
| SCHEMBL5136025 | 0.91 | TRPM8 (0.45) | TRPM8 | |
| SCHEMBL651505 | 0.90 | C5AR1 (0.40) | C5AR1TRPM8DHFRTSHRMMP13 | |
| SCHEMBL5135457 | 0.89 | TRPM8 (0.44) | C5AR1TRPM8PTGDR2 | |
| SCHEMBL5136578 | 0.89 | C5AR1 (0.43) | C5AR1TSHR | |
| SCHEMBL5136482 | 0.89 | C5AR1 (0.47) | C5AR1TSHR | |
| SCHEMBL648971 | 0.88 | C5AR1 (0.42) | C5AR1TRPM8DHFRMMP13PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |